Skip to main content

Viridian Therapeutics (VRDN) Receives a Buy from Wedbush

Tipranks - Tipranks - Tue Dec 23, 2025

In a report released on December 18, Laura Chico from Wedbush maintained a Buy rating on Viridian Therapeutics, with a price target of $47.00. The company’s shares closed last Friday at $31.60.

Claim 70% Off TipRanks This Holiday Season

According to TipRanks, Chico is a 5-star analyst with an average return of 11.4% and a 51.22% success rate. Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, BioCryst, and Denali Therapeutics.

In addition to Wedbush, Viridian Therapeutics also received a Buy from Evercore ISI’s Gavin Clark-Gartner in a report issued on December 18. However, on December 9, TR | OpenAI – 4o reiterated a Hold rating on Viridian Therapeutics (NASDAQ: VRDN).

See Insiders’ Hot Stocks on TipRanks >>

Based on Viridian Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $70.57 million and a GAAP net loss of $34.6 million. In comparison, last year the company earned a revenue of $86 thousand and had a GAAP net loss of $76.69 million

Read More on VRDN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).